By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Bristol-Myers Squibb Company 

345 Park Avenue

New York  New York  10154  U.S.A.
Phone: 212-546-4000 Fax: 212-546-4020


Key Statistics

Ownership: Public

Web Site: Bristol-Myers Squibb
Symbol: BMY



PanVera LLC 

Pharmagene Laboratories Limited 

Johnson & Johnson 

Amersham Biosciences 

Lexicon Genetics Incorporated 

Athersys  Athersys will provide Bristol-Myers Squibb with cell lines expressing validated drug targets produced using the RAGE-Validated Target technology. BMS plans to use its combinatorial chemistry capabilities to develop small molecule drug candidates against the validated targets.

Merck & Co.  Diabetes

Affinimark Technologies Inc. 

GlaxoSmithKline (North Carolina) 

Medarex, Inc. 

Gilead (Durham, NC) 

Phyton Biotech, Inc.  - Cancer

Gilead (Seattle, WA) 

Company News
Bristol-Myers Squibb (BMY) Release: FDA Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients 9/2/2015 11:05:28 AM
Bristol-Myers Squibb (BMY) and AbbVie (ABBV) Release: FDA Accepts For Priority Review The Biologics License Application For Empliciti (Elotuzumab) For The Treatment Of Multiple Myeloma In Patients Who Have Received One Or More Prior Therapies 9/1/2015 10:19:34 AM
Bristol-Myers Squibb (BMY) Bags Rights to Buy Promedior in Deal Worth $1.25 Billion 8/31/2015 6:41:58 AM
Bristol-Myers Squibb (BMY) and QIMR Berghofer Medical Research Institute Forge Pact to Discover New Immuno-Oncology Antibodies 8/31/2015 6:08:01 AM
Bristol-Myers Squibb (BMY) And Pfizer (PFE) To Present New Data On Eliquis (apixaban) At The ESC Congress 2015 8/24/2015 7:31:10 AM
R-PHARM Acquires IXEMPRA (Ixabepilone) From Bristol-Myers Squibb (BMY) And Launches U.S. Commercial Operations 8/17/2015 6:50:13 AM
Bristol-Myers Squibb (BMY) Release: FDA Approves U.S. Product Labeling Update For Sprycel (Dasatinib) To Include Five-Year First-Line And Seven-Year Second-Line Efficacy And Safety Data In Chronic Myeloid Leukemia In Chronic Phase 8/13/2015 10:33:11 AM
Bristol-Myers Squibb (BMY) Release: FDA Extends Action Date For Supplemental Biologics License Application For Opdivo (Nivolumab) In Previously Untreated Advanced Melanom 8/13/2015 6:02:49 AM
FDA Pushes Back Review Date on Bristol-Myers Squibb (BMY)'s Key Melanoma Drug Opdivo 8/13/2015 6:01:34 AM
uniQure (QURE) Announces Receipt Of $53 Million From Bristol-Myers Squibb (BMY) For Target Selection Payment And Additional Equity Investment 8/10/2015 7:42:42 AM